Analysis of Halper Sadeh's Investigation into SAGE, CHTR, and VIGL Shareholder Rights Halper Sadeh LLC is probing Sage Therapeutics, Charter Communications, and Vigil Neuroscience for potential shareholder rights violations following important corporate transactions. Learn your options.

Analysis of Halper Sadeh's Investigation into SAGE, CHTR, and VIGL Shareholder Rights #United_States #New_York #Sage #CHTR #VIGL

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Mon Jul 7th - #ZVRA #ZJK #XHG #VIGL #TRS #MDIA #LNSR #KRMD #BTCS #ALLR #OCFT #MUX #MED #AMPX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Investigation by Halper Sadeh LLC Targets HURA and VIGL Shareholder Rights Halper Sadeh LLC is investigating TuHURA and Vigil Neuroscience for potential shareholder rights violations. This inquiry seeks to protect investor interests and ensure compliance with securities laws.

Investigation by Halper Sadeh LLC Targets HURA and VIGL Shareholder Rights #USA #New_York #Halper_Sadeh #HURA #VIGL

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP Vigil Neuroscience announced disappointing results from its Phase 2 IGNITE trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). While the drug demonstrated favorable safety, tolerability, and pharmacokinetic profiles at both 20 mg/kg and 40 mg/kg doses, it failed to show beneficial effects on biomarker or clinical efficacy endpoints in ALSP patients. As a result, the company is discontinuing the Phase 2 long-term extension study. Despite the setback, Vigil's CEO highlighted the contributions of the ALSP community and noted that their research efforts have helped increase awareness and understanding of the disease.

#VIGL Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

www.stocktitan.net/news/VIGL/vigil-neurosci...

Vigil Neuroscience ($VIGL) jumps on news of a Sanofi acquisition worth up to $600M. The deal centers on a promising Alzheimer’s drug still in early trials.
Read more 👉 www.valuethemarkets.com/analysis/vig...

#VIGL #Sanofi #Biotech #PharmaNews #ValueTheMarkets

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu May 22d - #RXRX #HTZ #SEDG #JBLU #BTBT #VIGL #LAES #APLD #WULF #RUN #RIG #RGTI #QUBT #LUNR #LEU #KULR #EOSE #FUBO #ASST #AAP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Just In: ( NASDAQ: #VIGL ) Today's Top Stocks to Trade- SYTA, NVTS, BON, VIGL, and LGHL- SYTA, NVTS, BON, VIGL, and LGHL

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi - Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral

#VIGL Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

www.stocktitan.net/news/VIGL/vigil-neurosci...

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates Vigil Neuroscience (NASDAQ: VIGL) reported Q1 2025 financial results and provided updates on its TREM2 programs. The company's lead candidate iluzanebart is approaching final analysis from the IGNITE Phase 2 trial for ALSP in Q2 2025. Their second candidate, VG-3927, showed positive Phase 1 results for Alzheimer's disease, demonstrating favorable safety, once-daily dosing potential, and up to 50% reduction in sTREM2. The company plans to initiate a Phase 2 trial for VG-3927 in Q3 2025 with a 25mg daily dose. Financial results showed cash position of $87.1 million as of March 31, 2025, expected to fund operations into 2026. Q1 net loss increased to $22.4 million from $19.9 million year-over-year, with R&D expenses at $16.5 million and G&A expenses at $7.0 million.

#VIGL Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

www.stocktitan.net/news/VIGL/vigil-neurosci...

Clinical Data Breakthrough: Vigil's New Alzheimer's Drug Targets Both Aβ and Tau Pathologies Phase 1 trial reveals 50% sTREM2 reduction with Vigil's VG-3927, demonstrating promising dual-action approach for Alzheimer's treatment. Full analysis inside.

#VIGL Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

www.stocktitan.net/news/VIGL/vigil-neurosci...

Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success Vigil's oral TREM2 agonist demonstrates 50% CSF biomarker reduction in Phase 1, advancing to Phase 2 in Q3 2025. $97.8M cash runway extends operations into 2026.

#VIGL Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

www.stocktitan.net/news/VIGL/vigil-neurosci...

Vigil's Alzheimer's Drug Shows Promising Phase 1 Results with 50% Brain Biomarker Reduction Vigil Neuroscience's oral treatment VG-3927 demonstrates strong safety profile and significant brain penetration in Phase 1 trial, advancing to Phase 2 for Alzheimer's in 2025.

#VIGL Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

www.stocktitan.net/news/VIGL/vigil-neurosci...

Vigil Neuroscience Lands $40M Sanofi Investment, FDA Signals Path for Accelerated Approval Vigil Neuroscience secures major Sanofi backing while advancing TREM2 programs. FDA shows openness to fast-track approval for iluzanebart in ALSP treatment, with key trial data due in 2025.

#VIGL Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

www.stocktitan.net/news/VIGL/vigil-neurosci...

JUST IN: ( NASDAQ: #VIGL ) Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

#StockMarket #News